Published in BMC Cancer on November 15, 2010
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci (2011) 0.94
Ku80 cooperates with CBP to promote COX-2 expression and tumor growth. Oncotarget (2015) 0.84
Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients. Int J Cancer (2014) 0.82
Differential gene expression pattern in early gastric cancer by an integrative systematic approach. Int J Oncol (2012) 0.80
Household income is associated with the p53 mutation frequency in human breast tumors. PLoS One (2013) 0.79
Metabolic Signatures of Human Breast Cancer. Mol Cell Oncol (2015) 0.79
Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer. BMC Cancer (2015) 0.78
Cyclooxygenase-2 expression in central giant cell lesion of the jaws: an immunohistochemical study. J Mol Histol (2011) 0.78
Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice. Oncol Lett (2012) 0.77
Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC: is there evidence to support a prognostic or diagnostic role? Exp Hematol Oncol (2014) 0.77
Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer. BMC Cancer (2014) 0.76
Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging. Front Oncol (2013) 0.75
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer. Oncotarget (2016) 0.75
Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis. Oncotarget (2017) 0.75
Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer. Free Radic Biol Med (2015) 0.75
Role of Aspirin in Breast Cancer Survival. Curr Oncol Rep (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Role of translocation in the activation and function of protein kinase B. J Biol Chem (1997) 7.29
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol (2002) 2.56
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell (2004) 2.53
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem (2002) 2.29
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res (2002) 1.92
Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst (2006) 1.88
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol (2002) 1.76
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci U S A (2006) 1.62
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer (2006) 1.51
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer (2009) 1.38
Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer (2007) 1.38
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res (2005) 1.32
Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol (2004) 1.26
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev (2003) 1.26
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res (2004) 1.18
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest (2005) 1.14
Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology (2004) 1.08
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res (2005) 1.08
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res (2005) 1.07
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol (2008) 1.03
Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery (2002) 0.99
Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene (2004) 0.97
Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol (2008) 0.95
Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest (2007) 0.90
Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol (2006) 0.89
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat (2008) 0.88
EGFR and HER-2 antagonists in breast cancer. Anticancer Res (2007) 0.85
A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer (2006) 0.85
A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol (2008) 0.82
Elevated cyclooxygenase-2 expression is associated with histological grade in invasive ductal breast carcinoma. J Med Dent Sci (2005) 0.81
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
Pleural plaques and their effect on lung function in Libby vermiculite miners. Chest (2014) 3.21
The emerging biology of the nitrite anion. Nat Chem Biol (2005) 2.88
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol (2004) 2.61
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Identification, function and structure of the mycobacterial sulfotransferase that initiates sulfolipid-1 biosynthesis. Nat Struct Mol Biol (2004) 2.25
CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem (2006) 2.23
A stromal gene signature associated with inflammatory breast cancer. Int J Cancer (2008) 2.18
Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A (2005) 2.17
Increasing survival of ischemic tissue by targeting CD47. Circ Res (2007) 2.16
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
SURGICAL OUTCOME OF SIMULTANEOUS INTRAOCULAR LENS RESCUE AND SUTURELESS INTRASCLERAL TUNNEL FIXATION OF DISLOCATED INTRAOCULAR LENSES. Retina (2015) 2.01
Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol (2011) 1.97
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst (2006) 1.88
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate (2008) 1.86
A critique of the European Commission document, "State of the Art Assessment of Endocrine Disrupters". Crit Rev Toxicol (2012) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci U S A (2003) 1.78
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A (2003) 1.76
Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood (2007) 1.73
Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One (2009) 1.72
A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet (2011) 1.60
5'-Adenosinephosphosulphate reductase (CysH) protects Mycobacterium tuberculosis against free radicals during chronic infection phase in mice. Mol Microbiol (2006) 1.59
Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res (2006) 1.56
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood (2006) 1.56
Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A (2005) 1.55
Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet (2007) 1.55
Protein nitration is mediated by heme and free metals through Fenton-type chemistry: an alternative to the NO/O2- reaction. Proc Natl Acad Sci U S A (2002) 1.53
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest (2010) 1.52
Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea. J Gastroenterol Hepatol (2008) 1.52
Small molecule signaling agents: the integrated chemistry and biochemistry of nitrogen oxides, oxides of carbon, dioxygen, hydrogen sulfide, and their derived species. Chem Res Toxicol (2012) 1.51
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med (2009) 1.47
The reduction potential of nitric oxide (NO) and its importance to NO biochemistry. Proc Natl Acad Sci U S A (2002) 1.45
Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res (2006) 1.43
The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther (2006) 1.41
Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem (2007) 1.41
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res (2011) 1.39
Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol (2004) 1.38
Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer (2007) 1.38
Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis (2012) 1.38
The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem (2004) 1.37
Focusing of nitric oxide mediated nitrosation and oxidative nitrosylation as a consequence of reaction with superoxide. Proc Natl Acad Sci U S A (2002) 1.33
The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal (2006) 1.32
Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res (2013) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst (2012) 1.30
Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res (2008) 1.30
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One (2012) 1.30
Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med (2003) 1.28
CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy (2012) 1.27
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol (2008) 1.26
Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A (2007) 1.26
Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in Vivo. J Med Chem (2005) 1.26
Nitroxyl (HNO): chemistry, biochemistry, and pharmacology. Annu Rev Pharmacol Toxicol (2005) 1.25
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med (2011) 1.24